Rx3 Pharmaceuticals Expands Management Team
Anti-microbial company hires Chief Financial Officer to raise VC funds
PDF Version Available (67kb)
San Diego, CA, January 3, 2005 – Rx3 Pharmaceuticals, Inc., a drug discovery company,
announced today that it has hired John P. Schmid to serve as its Chief Financial Officer.
Mr. Schmid was previously co-founder and CFO of GeneFormatics as well as the first
CFO of Endonetics. Both firms were backed by major venture capital investors. Over
the past seven months, Mr. Schmid has served as an adviser and consultant to Rx3 in
forming, capitalizing, and launching the Company.
"We are so pleased to have John join our team to accelerate the Company’s development and capitalization," said John Finn, President of Rx3 Pharmaceuticals. "He played a major role in the formation of the Company and has been a valuable contributor since our inception. We are excited to have him working side by side with us as a colleague."
John Schmid said, "Having been involved in launching three companies previously, I can say that this company, its team, and its technology are much further developed than most start-ups. It's a pleasure to be in the company of such experienced colleagues."
About Rx3 Pharmaceuticals, Inc.
Rx3 Pharmaceuticals is a drug discovery company applying its structure-based drug
design technologies to antimicrobial programs. These programs target novel proteins in
validated pathways. Rx3's discovery team has advanced anti-bacterial programs into late
stage drug discovery and expects to identify development candidates in 2006. For more
information, visit www.rx3pharma.com.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements and are subject to risks and uncertainties that may cause actual results to differ materially from the results described in, or implied by, the forward-looking statements. Rx3 disclaims any intent or obligation to update these forward-looking statements.